Orthosteric versus allosteric GPCR activation: The great challenge of group-III mGluRs

Biochemical Pharmacology

Volumn 84, Issue 4, 2012, Pages 414-424

  Flor, Peter J ^a   Acher, Francine C ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

AMN082; GPCR; LSP1 2111; LSP4 2022; Metabotropic glutamate; PHCCC

Indexed keywords

1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; 2 (3,5 DICHLORPHENYLCARBAMOYL)CYCLOHEXANECARBOXYLIC ACID; 2 (4 BROMOBENZYLTHIO) N (4 SEC BUTYLPHENYL)ACETAMIDE; 2 AMINO 2 METHYL 4 PHOSPHONOBUTYRIC ACID; 2 AMINO 4 PHOSPHONOBUTYRIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 AMINO 3 CARBOXYPROPYL 2' CARBOXYETHYLPHOSPHINIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 PHOSPHONOPHENYLGLYCINE; 5 METHYL N (4 METHYLPYRIMIDIN 2 YL) 4 (1H PYRAZOL 4 YL)THIAZOL 2 AMINE; 6 (4 METHOXYPHENYL) 5 METHYL 3 (4 PYRIDINYL)ISOXAZOLO[4,5 C]PYRIDIN 4(5H) ONE; ADX 88178; AF 21934; ALPHA METHYL 4 PHOSPHONOPHENYLGLYCINE; ALPHA METHYLSERINE O PHOSPHATE; AMN 082; AZ 12216052; EGLUMETAD; LSP 12111; LSP 1308; LSP 42022; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 6; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR 8; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MICROTUBULE ASSOCIATED PROTEIN 4; N (3 CHLOROPHENYL)PICOLINAMIDE; N PHENYL 7 (HYDROXYLIMINO)CYCLOPROPA[B]CHROMEN 1A CARBOXYAMIDE; N,N' DIBENZHYDRYLETHANE 1,2 DIAMINE; N1 (3,4 DICHLOROPHENYL)CYCLOHEXANE 1,2 DICARBOXAMIDE; PHOSPHOSERINE; POMAGLUMETAD METHIONIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VU 0155041; VU 0364770; [(3 AMINO 3 CARBOXY)PROPYL][(4 HYDROXY 5 METHOXY 3 NITROPHENYL)HYDROXYMETHYL]PHOSPHINIC ACID; [(3 AMINO 3 CARBOXY)PROPYL][[4 (CARBOXYMETHOXY)PHENYL]HYDROXYMETHYL]PHOSPHINIC ACID; [3 [3 AMINO 3 CARBOXYPROPYL(HYDROXY)PHOSPHINYL]HYDROXYMETHYL] 5 NITROTHIOPHENE;

ALLOSTERISM; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; STEREOSPECIFICITY;

EID: 84864116271     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.04.013     Document Type: Note

References (98)

1. S. Nakanishi Molecular diversity of glutamate receptors and implications for brain function Science 258 1992 597 603
2. C.M. Niswender, and P.J. Conn Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu Rev Pharmacol Toxicol 50 2010 295 322
3. F. Nicoletti, J. Bockaert, G.L. Collingridge, P.J. Conn, F. Ferraguti, and D.D. Schoepp Metabotropic glutamate receptors: from the workbench to the bedside Neuropharmacology 60 7-8 2011 1017 1041
4. D. Berg, J. Godau, C. Trenkwalder, K. Eggert, I. Csoti, and A. Storch AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials Mov Disord 26 7 2011 1243 1250
5. M.J. Fell, D.L. McKinzie, J.A. Monn, and K.A. Svensson Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia Neuropharmacology 62 3 2012 1473 1483
6. J. Levenga, S. Hayashi, F.M. de Vrij, S.K. Koekkoek, H.C. van der Linde, and I. Nieuwenhuizen AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome Neurobiol Dis 42 3 2011 311 317
7. A. Yasuhara, and S. Chaki Metabotropic glutamate receptors: potential drug targets for psychiatric disorders Open Med Chem J 4 2010 20 36
8. M.J. Marino, D.L.J. Williams, J.A. O'Brien, O. Valenti, T.P. McDonald, and M.K. Clements Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment Proc Natl Acad Sci U S A 100 23 2003 13668 13673
9. G. Battaglia, C.L. Busceti, G. Molinaro, F. Biagioni, A. Traficante, and F. Nicoletti Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine J Neurosci 26 27 2006 7222 7229
10. K. Mitsukawa, R. Yamamoto, S. Ofner, J. Nozulak, O. Pescott, and S. Lukic A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo Proc Natl Acad Sci U S A 102 51 2005 18712 18717
11. B. Greco, S. Lopez, H. van der Putten, P.J. Flor, and M. Amalric Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease J Pharmacol Exp Ther 332 3 2010 1064 1071
12. M. Broadstock, P.J. Austin, M.J. Betts, and S. Duty Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata Br J Pharmacol 165 4b 2012 1034 1045
13. C.K. Jones, M. Bubser, A.D. Thompson, J.W. Dickerson, N. Turle-Lorenzo, and M. Amalric The mGlu4 positive allosteric modulator VU0364770 produces efficacy alone and in combination with l-DOPA or an adenosine A2A antagonist in preclinical rodent models of Parkinson's disease J Pharmacol Exp Ther 340 2 2012 404 421
14. S. Chiechio, and F. Nicoletti Metabotropic glutamate receptors and the control of chronic pain Curr Opin Pharmacol 12 1 2012 28 34
15. A. Pilc, S. Chaki, G. Nowak, and J.M. Witkin Mood disorders: regulation by metabotropic glutamate receptors Biochem Pharmacol 75 5 2008 997 1006
16. J.M. Wieronska, K. Stachowicz, A. Pałucha-Poniewiera, F. Acher, P. Branski, and A. Pilc Metabotropic glutamate receptor 4 novel agonist LSP 1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems Neuropharmacology 59 7-8 2010 627 634
17. J. Wieronska, K. Stachowicz, F. Acher, T. Lech, and A. Pilc Opposite efficacy of group III mGlu receptors activators, LSP 1-2111 and AMN082, in animal models of positive symptoms of schizophrenia Psychopharmacology 220 3 2012 481 494
18. M. Fendt, S. Schmid, D.R. Thakker, L.H. Jacobson, R. Yamamoto, and K. Mitsukawa mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity Mol Psychiatry 13 10 2008 970 979
19. X. Li, J. Li, X.Q. Peng, K. Spiller, E.L. Gardner, and Z.X. Xi Metabotropic glutamate receptor 7 modulates the rewarding effects of cocaine in rats: involvement of a ventral pallidal GABAergic mechanism Neuropsychopharmacology 34 7 2009 1783 1796
20. A. Bahi, K. Fizia, M. Dietz, F. Gasparini, and P.J. Flor Pharmacological modulation of mGluR7 with AMN082 and MMPIP exerts specific influences on alcohol consumption and preference in rats Addict Biol 17 2 2012 235 247
21. I. Toth, M. Dietz, D. Peterlik, S.E. Huber, M. Fendt, and I.D. Neumann Pharmacological interference with metabotropic glutamate receptor subtype 7 but not subtype 5 differentially affects within- and between-session extinction of Pavlovian conditioned fear Neuropharmacology 62 4 2012 1619 1626
22. H. Goddyn, Z. Callaerts-Vegh, S. Stroobants, T. Dirikx, D. Vansteenwegen, and D. Hermans Deficits in acquisition and extinction of conditioned responses in mGluR7 knockout mice Neurobiol Learn Mem 90 1 2008 103 111
23. B. Gyetvai, A. Simonyi, M. Oros, M. Saito, J. Smiley, and C. Vadasz mGluR7 genetics and alcohol: intersection yields clues for addiction Neurochem Res 36 6 2011 1087 1100
24. S. Schmid, and M. Fendt Effects of the mGluR8 agonist (S)-3,4-DCPG in the lateral amygdala on acquisition/expression of fear-potentiated startle, synaptic transmission, and plasticity Neuropharmacology 50 2 2006 154 164
25. R.M. Duvoisin, T. Pfankuch, J.M. Wilson, J. Grabell, V. Chhajlani, and D.G. Brown Acute pharmacological modulation of mGluR8 reduces measures of anxiety Behav Brain Res 212 2 2010 168 173
26. R.M. Duvoisin, L. Villasana, M.J. Davis, D.G. Winder, and J. Raber Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges Behav Brain Res 221 1 2011 50 54
27. R.M. Duvoisin, C. Zhang, T.F. Pfankuch, H. O'Connor, J. Gayet-Primo, and S. Quraishi Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8 Eur J Neurosci 22 2 2005 425 436
28. A.M. Linden, B.G. Johnson, S.C. Peters, H.E. Shannon, M. Tian, and Y. Wang Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor Neuropharmacology 43 2 2002 251 259
29. M. Fendt, H. Burki, S. Imobersteg, H. van der Putten, K. McAllister, and J.C. Leslie The effect of mGlu8 deficiency in animal models of psychiatric diseases Genes Brain Behav 9 1 2010 33 44
30. J. Folbergrova, R. Druga, R. Haugvicova, P. Mares, and J. Otahal Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid Neuropharmacology 54 4 2008 665 675
31. J. Folbergrova, R. Haugvicova, and P. Mares Seizures induced by homocysteic acid in immature rats are prevented by group III metabotropic glutamate receptoragonist (R,S)-4-phosphonophenylglycine Exp Neurol 180 1 2003 46 54
32. F. Gasparini, V. Bruno, G. Battaglia, S. Lukic, T. Leonhardt, and W. Inderbitzin (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo J Pharmacol Exp Ther 289 3 1999 1678 1687
33. R.X. Moldrich, A.G. Chapman, G. De Sarro, and B.S. Meldrum Glutamate metabotropic receptors as targets for drug therapy in epilepsy Eur J Pharmacol 476 1-2 2003 3 16
34. G. Sansig, T.J. Bushell, V.R. Clarke, A. Rozov, N. Burnashev, and C. Portet Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7 J Neurosci 21 22 2001 8734 8745
35. E. Szczurowska, and P. Mares Controversial action of positive modulator of subtype 7 of metabotropic glutamate receptors AMN082 on cortical epileptic afterdischarges in immature rats Eur J Pharmacol 623 1-3 2009 37 40
36. K. Klak, A. Palucha, P. Branski, M. Sowa, and A. Pilc Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats Amino Acids 32 2 2007 169 172
37. A. Palucha, K. Klak, P. Branski, H. van der Putten, P.J. Flor, and A. Pilc Activation of the mGlu7 receptor elicits antidepressant-like effects in mice Psychopharmacology (Berl) 194 4 2007 555 562
38. S.R. Bradley, J.M. Uslaner, R.B. Flick, A. Lee, K.M. Groover, and P.H. Hutson The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling Pharmacol Biochem Behav 101 1 2012 35 40
39. A. Nomura, R. Shigemoto, Y. Nakamura, N. Okamoto, N. Mizuno, and S. Nakanishi Developmentally regulated postsynaptic localization of a metabotropic glutamate receptor in rat rod bipolar cells Cell 77 3 1994 361 369
40. C. Zeitz, U. Forster, J. Neidhardt, S. Feil, S. Kalin, and D. Leifert Night blindness-associated mutations in the ligand-binding, cysteine-rich, and intracellular domains of the metabotropic glutamate receptor 6 abolish protein trafficking Hum Mutat 28 8 2007 771 780
41. J. Cartmell, and D.D. Schoepp Regulation of neurotransmitter release by metabotropic glutamate receptors J Neurochem 75 3 2000 889 907
42. R. Martin, M. Torres, and J. Sanchez-Prieto mGluR7 inhibits glutamate release through a PKC-independent decrease in the activity of P/Q-type Ca2+ channels and by diminishing cAMP in hippocampal nerve terminals Eur J Neurosci 26 2 2007 312 322
43. R. Martin, T. Durroux, F. Ciruela, M. Torres, J.P. Pin, and J. Sanchez-Prieto The metabotropic glutamate receptor mGlu7 activates phospholipase C, translocates munc-13-1 protein, and potentiates glutamate release at cerebrocortical nerve terminals J Biol Chem 285 23 2010 17907 17917
44. H.-O. Bertrand, A.-S. Bessis, J.-P. Pin, and F.C. Acher Common and selective molecular determinants involved in metabotropic glutamate receptor agonist activity J Med Chem 45 15 2002 3171 3183
45. N. Kunishima, Y. Shimada, Y. Tsuji, T. Sato, M. Yamamoto, and T. Kumasaka Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor Nature 407 2000 971 977
46. T. Muto, D. Tsuchiya, K. Morikawa, and H. Jingami Structures of the extracellular regions of the group II/III metabotropic glutamate receptors Proc Natl Acad Sci U S A 104 10 2007 3759 3764
47. H. Lavreysen, and F.M. Dautzenberg Therapeutic potential of group III metabotropic glutamate receptors Curr Med Chem 15 7 2008 671 684
48. A.-S. Bessis, P. Rondard, F. Gaven, I. Brabet, N. Triballeau, and L. Prézeau Closure of the Venus Flytrap module of mGlu8 receptor and the activation process: insights from mutations converting antagonists into agonists Proc Natl Acad Sci U S A 99 17 2002 11097 11102
49. M.L. Parmentier, T. Galvez, F. Acher, B. Peyre, R. Pellicciari, and Y. Grau Conservation of the ligand recognition site of metabotropic glutamate receptors during evolution Neuropharmacology 39 7 2000 1119 1131
50. F. Acher, and H.-O. Bertrand Amino acid recognition by Venus Flytrap domains is encoded in an 8 residue motif Biopolymers 80 2-3 2005 357 366
51. D.D. Schoepp, D.E. Jane, and J.A. Monn Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38 1999 1431 1476
52. S. Wu, R.A. Wright, P.K. Rockey, S.G. Burgett, J.S. Arnold, and P.R. Rosteck Jr. Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells Brain Res Mol Brain Res 53 1-2 1998 88 97
53. P.J. Flor, G. Battaglia, F. Nicoletti, F. Gasparini, and V. Bruno Neuroprotective activity of metabotropic glutamate receptor ligands Adv Exp Med Biol 513 2002 197 223
54. V. Bruno, G. Battaglia, I. Ksiazek, H. van der Putten, M.V. Catania, and R. Giuffrida Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death J Neurosci 20 17 2000 6413 6420
55. F. Acher, F. Tellier, I. Brabet, L. Fagni, R. Azerad, and J.-P. Pin Synthesis and pharmacological characterization of aminocyclopentane tricarboxylic acids (ACPT): new tools to discriminate between metabotropic glutamate receptor subtypes J Med Chem 40 19 1997 3119 3129
56. N.K. Thomas, R.A. Wright, P.A. Howson, A.E. Kingston, D.D. Schoepp, and D.E. Jane (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord Neuropharmacology 40 3 2001 311 318
57. R.X. Moldrich, P.M. Beart, D.E. Jane, A.G. Chapman, and B.S. Meldrum Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice Neuropharmacology 40 5 2001 732 735
58. A. Palucha-Poniewiera, A. Klodzinska, K. Stachowicz, K. Tokarski, G. Hess, and S. Schann Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents Neuropharmacology 55 4 2008 517 524
59. A.G. Chapman, A. Talebi, P.K. Yip, and B.S. Meldrum Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1- aminocyclopentane-1,2,4-tricarboxylic acid Eur J Pharmacol 424 2 2001 107 113
60. M. Ghauri, A.G. Chapman, and B.S. Meldrum Convulsant and anticonvulsant actions of agonists and antagonists of group III mGluRs Neuroreport 7 9 1996 1469 1474
61. H. Hikichi, T. Murai, S. Okuda, S. Maehara, A. Satow, and S. Ise Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H) -one (MMPIP), on the central nervous system in rodents Eur J Pharmacol 639 1-3 2010 106 114
62. J.F. Cryan, P.H. Kelly, H.C. Neijt, G. Sansig, P.J. Flor, and H. van Der Putten Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7 Eur J Neurosci 17 11 2003 2409 2417
63. C.M. Niswender, K.A. Johnson, N.R. Miller, J.E. Ayala, Q. Luo, and R. Williams Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7 Mol Pharmacol 77 3 2010 459 468
64. G. Suzuki, N. Tsukamoto, H. Fushiki, A. Kawagishi, M. Nakamura, and H. Kurihara In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists J Pharmacol Exp Ther 323 1 2007 147 156
65. P. Sibille, S. Lopez, I. Brabet, O. Valenti, N. Oueslati, and F. Gaven Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropane carboxylic acids, new group III metabotropic glutamate receptor agonists J Med Chem 50 15 2007 3585 3595
66. K. Stachowicz, A. Klodzinska, A. Palucha-Poniewiera, S. Schann, P. Neuville, and A. Pilc The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems Neuropharmacology 57 3 2009 227 234
67. S. Lopez, N. Turle-Lorenzo, F. Acher, E. De Leonibus, A. Mele, and M. Amalric Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease J Neurosci 27 25 2007 6701 6711
68. C. Goudet, E. Chapuy, A. Alloui, F. Acher, J.-P. Pin, and A. Eschalier Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain Pain 137 2008 112 124
69. C. Selvam, N. Oueslati, I.A. Lemasson, I. Brabet, D. Rigault, and T. Courtiol A virtual screening hit reveals new possibilities to develop group III metabotropic glutamate receptor agonists J Med Chem 53 2010 2797 2813
70. N. Triballeau, F. Acher, I. Brabet, J.-P. Pin, and H.-O. Bertrand Virtual screening workflow development guided by the ROC curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4 J Med Chem 48 7 2005 2534 2547
71. P.A. Johansen, L.A. Chase, A.D. Sinor, J.F. Koerner, R.L. Johnson, and M.B. Robinson Type 4a metabotropic glutamate receptor: identification of new potent agonists and differenciation from the l-(+)-2-amino-4-phosphonobutanoic acid-sensitive receptor in the lateral perforant pathway in rats Mol Pharmacol 46 1995 140 149
72. C. Selvam, C. Goudet, N. Oueslati, J.-P. Pin, and F. Acher l-(+)-2-amino-4-thiophosphonobutyric acid (l-thioAP4), a new potent agonist of group III metabotropic glutamate receptors: increased distal acidity affords enhanced potency J Med Chem 50 19 2007 4656 4664
73. D. Cuomo, G. Martella, E. Barabino, P. Platania, D. Vita, and G. Madeo Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment J Neurochem 109 2009 1096 1105
74. C. Beurrier, S. Lopez, D. Révy, C. Selvam, C. Goudet, and M. Lhérondel Electrophysiological and behavioral evidences that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism FASEB J 23 10 2009 3619 3628
75. C. Goudet, B. Vilar, T. Courtiol, T. Deltheil, T. Bessiron, I. Brabet, N. Oueslati, D. Rigault, H.-O. Bertrand, H. McLean, H. Daniel, M. Amalric, F.C. Acher, and J.-P. Pin A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential FASEB J 26 4 2012 1682 1693
76. F.C. Acher, C. Selvam, J.-P. Pin, C. Goudet, and H.-O. Bertrand A critical pocket close to the glutamate binding site of mGlu receptors opens new possibilities for agonist design Neuropharmacology 60 1 2011 102 107
77. R. Dutzler The structural basis of ClC chloride channel function Trends Neurosci 27 6 2004 315 320
78. D. Doller, S.-P. Hong, K.G. Liu, M.D. Bacolod, M.A. Uberti, M. Cajina, F. Acher, and Gubellini P Disposition characteristics and functional activity of LSP 1-2111, an orthosteric Group III metabotropic glutamate receptor agonist American Chemical Society 242nd National meeting: MEDI285 2011
79. J.A. Monn, M.J. Valli, B.G. Johnson, C.R. Salhoff, R.A. Wright, and T. Howe Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase J Med Chem 39 1996 2990 3000
80. J.A. Monn, M.J. Valli, S.M. Massey, R.A. Wright, C.R. Salhoff, and B.G. Johnson Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties J Med Chem 40 1997 528 537
81. P.D. Dobson, and D.B. Kell Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7 3 2008 205 220
82. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, and B.V. Andreev Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat Med 13 9 2007 1102 1107
83. S. Litschig, F. Gasparini, D. Rueegg, N. Stoehr, P.J. Flor, and I. Vranesic CPCCOEt, a noncompetitive metabotropic glutamate receptor1 antagonist, inhibits receptor signaling without affecting glutamate binding Mol Pharmacol 55 3 1999 453 461
84. A. Pagano, D. Ruegg, S. Litschig, N. Stoehr, C. Stierlin, and M. Heinrich The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors J Biol Chem 275 43 2000 33750 33758
85. M. Maj, V. Bruno, Z. Dragic, R. Yamamoto, G. Battaglia, and W. Inderbitzin (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection Neuropharmacology 45 2003 895 906
86. F. Gasparini, K. Lingenhohl, N. Stoehr, P.J. Flor, M. Heinrich, and I. Vranesic 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacology 38 10 1999 1493 1503
87. M.A. Varney, N.D. Cosford, C. Jachec, S.P. Rao, A. Sacaan, and F.F. Lin SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5 J Pharmacol Exp Ther 290 1 1999 170 181
88. R. Zhang, and X. Xie Tools for GPCR drug discovery Acta Pharmacol Sin 2012
89. C.M. Niswender, K.A. Johnson, C.D. Weaver, C.K. Jones, Z. Xiang, and Q. Luo Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 Mol Pharmacol 74 5 2008 1345 1358
90. S. Célanire, and B. Campo Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders Expert Opin Drug Discov 7 3 2012 261 280
91. J.E. Ayala, C.M. Niswender, Q. Luo, J.L. Banko, and P.J. Conn Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated Neuropharmacology 54 5 2008 804 814
92. L. Di, and E.H. Kerns Profiling drug-like properties in discovery research Curr Opin Chem Biol 7 3 2003 402 408
93. K. Sugano, M. Kansy, P. Artursson, A. Avdeef, S. Bendels, and L. Di Coexistence of passive and carrier-mediated processes in drug transport Nat Rev Drug Discov 9 8 2010 597 614
94. J.M. Mathiesen, and M.T. Ramirez The metabotropic glutamate receptor 4 is internalized and desensitized upon protein kinase C activation Br J Pharmacol 148 3 2006 279 290
95. K.A. Pelkey, X. Yuan, G. Lavezzari, K.W. Roche, and C.J. McBain mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082 Neuropharmacology 52 1 2007 108 117
96. M.P. Gleeson, A. Hersey, D. Montanari, and J. Overington Probing the links between in vitro potency, ADMET and physicochemical parameters Nat Rev Drug Discov 10 3 2011 197 208
97. R. Kuhn, A. Pagano, N. Stoehr, I. Vranesic, P.J. Flor, and K. Lingenhohl In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article Amino Acids 23 1-3 2002 207 211
98. S.J. Sukoff Rizzo, S.K. Leonard, A. Gilbert, P. Dollings, D.L. Smith, and M.Y. Zhang The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther 338 1 2011 345 352